EVALUATION OF WHITE BLOOD CELL GROWTH FACTOR (WBCGF) USE IN METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

被引：0
|
作者：
Hoverman, J. R. [1 ]
Sheth, S. [1 ]
Clayton, M. [1 ]
Garey, J. [1 ]
Beveridge, R. [1 ]
机构：
[1] US Oncol Network McKesson Specialty Hlth, Level Pathways Task Force 1, The Woodlands, TX USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：425 / 426
页数：2
相关论文
共 50 条
  • [1] Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC)
    Wei, Jia
    Moran, Teresa
    Zou, Zhengyun
    Qian, Xiaoping
    Wang, Lifeng
    Camps, Carlos
    Hu, Wenjing
    Chaib, Imane
    Sanchez, Belen
    Xu, Lixia
    Karachaliou, Niki
    Sanchez-Ronco, Maria
    Liu, Baorui
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (03) : 180 - 188
  • [2] Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.
    Remon, Jordi
    Faivre, Laura
    Facchinetti, Francesco
    Bluthgen, Maria Virginia
    Pignon, Jean-Pierre
    Planchard, David
    Lacroix, Ludovic
    Besse, Benjamin
    Soria, Jean-Charles
    Caramella, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Sitravatinib plus tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
    Zhou, Q.
    Yu, X.
    Gao, B.
    Ma, Z.
    Chu, Q.
    Huang, D.
    Zhao, J.
    Day, D.
    Body, A. L.
    Pan, H.
    Cui, J.
    Li, H.
    Sun, J.
    Zhang, J.
    Fei, C.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2022, 33 : S1 - S2
  • [4] Sitravatinib plus tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
    Zhou, Q.
    Yu, X.
    Gao, B.
    Ma, Z.
    Chu, Q.
    Huang, D.
    Zhao, J.
    Day, D.
    Body, A. L.
    Pan, H.
    Cui, J.
    Chen, C.
    Xiang, X.
    Fei, C.
    Yang, L.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2021, 32 : S996 - S997
  • [5] EVALUATION OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG-CANCER (NSCLC)
    FOEMMEL, RS
    ALEXANDER, NA
    HIRSHAUT, Y
    KATOPODIS, N
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 182 - 182
  • [6] Does blood sugar impact on metastatic non-small cell lung cancer (NSCLC) outcome?
    Gravel, Mathieu
    Blais, Normand
    Tehfe, Mustapha Ali
    Florescu, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Non-small cell lung cancer (NSCLC) in elderly patients
    Batura-Gabryel, H.
    Brajer, B.
    LUNG CANCER, 2006, 52 : S19 - S19
  • [8] Effect of primary tumor size in patients with metastatic non-small cell lung cancer (NSCLC).
    Xia, Bing
    Gao, Feng
    Govindan, Ramaswamy
    Morgensztern, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Comorbidity in clinical trial patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Kosov, Maxim
    Kumar, Akhil
    Belotserkovskiy, Maxim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Screening for mutations in Colombian metastatic non-small cell lung cancer (NSCLC) patients (ONCOLGroup).
    Cardona, A. F.
    Ramos, P. L.
    Duarte, R.
    Carranza, H.
    Castro, C. J.
    Lema, M.
    Vargas, C. A.
    Jimenez, A.
    Becerra, H. A.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345